CD274 and neoplasm: Metastatic EBV + GC patients who were treated with pembrolizumab, a PD-1/PD-L1 inhibitor, showed good responses, and the favorable prognosis is reliant on high levels of PD-L1 and the number of infiltrating CD8+ T cells in the tumor [139].